risedronic acid has been researched along with osteoprotegerin in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (56.25) | 29.6817 |
| 2010's | 7 (43.75) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hiraoka, BY; Horiuchi, H; Kobayashi, Y; Matsuura, S; Miyazawa, H; Mogi, M; Nakamura, H; Nakamura, M; Ozawa, H; Saito, N; Takahashi, N; Takaoka, K; Udagawa, N | 1 |
| Cioffi, M; De Filippo, G; Di Domenico, G; Mossetti, G; Nunziata, V; Postiglione, L; Rendina, D; Viceconti, R | 1 |
| Dobnig, H; Fahrleitner-Pammer, A; Hofbauer, LC; Obermayer-Pietsch, B; Viereck, V | 1 |
| Bernabei, P; Brianza, SZ; Cristofaro, MA; D'Amelio, P; Di Bella, S; Grimaldi, A; Isaia, G; Pescarmona, GP; Ravazzoli, MG; Tamone, C | 1 |
| Morishita, M; Nagashima, M; Takahashi, H; Takenouchi, K; Wauke, K | 1 |
| Anastasilakis, AD; Avramidis, A; Gerou, S; Goulis, DG; Kita, M; Koukoulis, G; Polyzos, SA | 1 |
| Kanzaki, S; Matsuo, K; Ogawa, K; Takada, Y | 1 |
| Brookler, K | 1 |
| Cakir, T; Ciftci, IH; Dundar, U; Evcik, D; Kavuncu, V; Solak, O | 1 |
| Akyuz, G; Ay, P; Bizargity, P; Karadag-Saygi, E | 1 |
| Gulseren, A; Peyman, B; Pinar, A | 1 |
| Bai, XC; Chen, JT; Huang, MJ; Jin, DD; Jin, J; Lai, PL; Wang, L; Wang, XK; Zhong, ZM | 1 |
| Atkinson, EJ; Gössl, M; Kane, TL; Khosla, S; Lerman, A; McCready, LK; McGregor, UI; Peris, P | 1 |
| Feldbrin, Z; Luckish, A; Shargorodsky, M | 1 |
| Furuya, Y; Kobayashi, Y; Koide, M; Nakamura, M; Ninomiya, T; Ozaki, Y; Takahashi, N; Udagawa, N; Yasuda, H; Yoshinari, N | 1 |
| Cao, Y; Cheng, Y; Gan, L; Huang, P; Meng, B; Wu, D | 1 |
9 trial(s) available for risedronic acid and osteoprotegerin
| Article | Year |
|---|---|
Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Collagen Type I; Etidronic Acid; Female; Hip; Humans; Osteocalcin; Osteoporosis; Osteoprotegerin; Postmenopause; Prospective Studies; RANK Ligand; Risedronic Acid | 2006 |
Risedronate reduces osteoclast precursors and cytokine production in postmenopausal osteoporotic women.
Topics: Aged; Bone Density Conservation Agents; Calcium; Cell Survival; Cells, Cultured; Colony-Forming Units Assay; Etidronic Acid; Female; Humans; Middle Aged; Osteoclasts; Osteoporosis, Postmenopausal; Osteoprotegerin; Postmenopause; RANK Ligand; Risedronic Acid; Stem Cells; Time Factors; Tumor Necrosis Factor-alpha; Vitamin D | 2008 |
Osteoclast inhibitory effects of vitamin K2 alone or in combination with etidronate or risedronate in patients with rheumatoid arthritis: 2-year results.
Topics: Aged; Alkaline Phosphatase; Arthritis, Rheumatoid; Bone Density; Bone Density Conservation Agents; Cohort Studies; Collagen Type I; Drug Therapy, Combination; Etidronic Acid; Female; Humans; Male; Middle Aged; Osteoclasts; Osteoporosis; Osteoprotegerin; Peptides; Prednisolone; Prospective Studies; RANK Ligand; Risedronic Acid; Vitamin K 2 | 2008 |
Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: a randomized, controlled trial.
Topics: Aged; Biomarkers; Bone Density Conservation Agents; Calcium; Collagen Type I; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Osteoprotegerin; RANK Ligand; Risedronic Acid; Teriparatide | 2008 |
The effect of risedronate treatment on serum cytokines in postmenopausal osteoporosis: a 6-month randomized and controlled study.
Topics: Aged; Alkaline Phosphatase; Bone Density; Bone Density Conservation Agents; Calcium; Collagen Type I; Cytokines; Etidronic Acid; Female; Humans; Interleukin-1beta; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Osteoprotegerin; Peptides; RANK Ligand; Risedronic Acid; Tumor Necrosis Factor-alpha; Turkey; Vitamin D | 2009 |
The effect of risedronate treatment on serum osteoprotegerin and bone marker levels in postmenopausal women with osteoporosis.
Topics: Adult; Aged; Biomarkers; Bone and Bones; Bone Density; Bone Density Conservation Agents; Calcium; Etidronic Acid; Female; Femur; Follow-Up Studies; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Osteoprotegerin; Risedronic Acid; Vitamin D | 2011 |
Evaluation of weekly risedronate treatment in postmenopausal women with osteoprotegerin.
Topics: Aged; Amino Acids; Bone and Bones; Bone Density; Bone Density Conservation Agents; Collagen Type I; Etidronic Acid; Female; Humans; Middle Aged; Osteocalcin; Osteoprotegerin; Postmenopause; Risedronic Acid; Vitamin D | 2011 |
Effects of bisphosphonate treatment on circulating osteogenic endothelial progenitor cells in postmenopausal women.
Topics: Biomarkers; Bone Density; Bone Density Conservation Agents; C-Reactive Protein; Calcium; Creatinine; Double-Blind Method; Down-Regulation; Endothelium; Enzyme-Linked Immunosorbent Assay; Etidronic Acid; Female; Flow Cytometry; Gene Expression Regulation; Humans; Interleukin-8; Middle Aged; Osteoblasts; Osteogenesis; Osteoporosis, Postmenopausal; Osteoprotegerin; Phosphorus; Placebos; RANK Ligand; Risedronic Acid; Stem Cells; Treatment Outcome; Vitamin D | 2013 |
Effects of long-term risedronate treatment on serum ferritin levels in postmenopausal women with osteoporosis: the impact of cardiovascular risk factor load.
Topics: Aged; Bone Density Conservation Agents; C-Reactive Protein; Cardiovascular Diseases; Female; Ferritins; Fibrinogen; Glycated Hemoglobin; Humans; Insulin; Linear Models; Lipids; Lipoproteins, HDL; Middle Aged; Osteoporosis, Postmenopausal; Osteoprotegerin; Postmenopause; Prospective Studies; Pulse Wave Analysis; Research Design; Risedronic Acid; Risk Factors; Time Factors | 2016 |
7 other study(ies) available for risedronic acid and osteoprotegerin
| Article | Year |
|---|---|
Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption.
Topics: Animals; Bone and Bones; Bone Morphogenetic Protein 2; Bone Morphogenetic Proteins; Bone Resorption; Calcium; Calcium Channel Blockers; Carrier Proteins; Etidronic Acid; Glycoproteins; Male; Membrane Glycoproteins; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Osteocalcin; Osteogenesis; Osteoprotegerin; Phosphorus; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Risedronic Acid; Transforming Growth Factor beta | 2003 |
Interleukin-6 and osteoprotegerin systems in Paget's disease of bone: relationship to risedronate treatment.
Topics: Aged; Etidronic Acid; Female; Glycoproteins; Humans; Interleukin-6; Male; Middle Aged; Osteitis Deformans; Osteoprotegerin; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Risedronic Acid | 2005 |
Bisphosphonate therapy ameliorates hearing loss in mice lacking osteoprotegerin.
Topics: Animals; Bone Density Conservation Agents; Cochlea; Diphosphonates; Etidronic Acid; Evoked Potentials, Auditory, Brain Stem; Female; Hearing; Hearing Loss; Mice; Mice, Inbred C57BL; Mice, Transgenic; Osteoprotegerin; Risedronic Acid; Time Factors | 2009 |
Medical treatment of otosclerosis: rationale for use of bisphosphonates.
Topics: Aged; Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Cell Death; Combined Modality Therapy; Diphosphonates; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Ear, Inner; Ear, Middle; Etidronic Acid; Follow-Up Studies; Hearing Aids; Hearing Loss, Sensorineural; Humans; Male; Middle Aged; Osteoclasts; Osteoprotegerin; Otosclerosis; Risedronic Acid; Speech Discrimination Tests; Speech Reception Threshold Test; Stapes Surgery; Tinnitus | 2008 |
Risedronate inhibits bone marrow mesenchymal stem cell adipogenesis and switches RANKL/OPG ratio to impair osteoclast differentiation.
Topics: Adipogenesis; Bone Density Conservation Agents; Bone Marrow Cells; Cell Differentiation; Cells, Cultured; Dose-Response Relationship, Drug; Etidronic Acid; Humans; Mechanistic Target of Rapamycin Complex 1; Mesenchymal Stem Cells; Multiprotein Complexes; Osteoclasts; Osteoprotegerin; RANK Ligand; Risedronic Acid; TOR Serine-Threonine Kinases | 2013 |
Treatment of OPG-deficient mice with WP9QY, a RANKL-binding peptide, recovers alveolar bone loss by suppressing osteoclastogenesis and enhancing osteoblastogenesis.
Topics: Adaptor Proteins, Signal Transducing; Alveolar Bone Loss; Animals; Bone Density Conservation Agents; Disease Models, Animal; Drug Evaluation, Preclinical; Glycoproteins; Intercellular Signaling Peptides and Proteins; Male; Mice, Inbred C57BL; Mice, Knockout; Osteoblasts; Osteoclasts; Osteogenesis; Osteoprotegerin; Peptides, Cyclic; RANK Ligand; Risedronic Acid; Tibia | 2017 |
The effect of risedronate on orthodontic tooth movement in ovariectomized rats.
Topics: Animals; Cathepsin K; Female; Osteoclasts; Osteoprotegerin; Ovariectomy; RANK Ligand; Rats; Rats, Sprague-Dawley; Risedronic Acid; Tooth Movement Techniques | 2019 |